Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, Orexigen Discussing CV Risk Study For Weight-Loss Drug Contrave

This article was originally published in The Pink Sheet Daily

Executive Summary

Timing of the study to be discussed at Dec. 7 advisory committee meeting.
Advertisement

Related Content

FDA Panel Backs Approval Of Takeda/Orexigen's Obesity Drug Contrave
FDA Panel Backs Approval Of Orexigen's Obesity Drug Contrave
FDA Panel Backs Approval Of Orexigen's Obesity Drug Contrave
Arena and Vivus Take Divergent Paths To CRL Response
REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance
Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression
Sanofi Withdraws Zimulti NDA For Weight Loss

Topics

Advertisement
UsernamePublicRestriction

Register

PS071561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel